Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;91(5):1057-65.
doi: 10.4269/ajtmh.14-0145. Epub 2014 Oct 6.

Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, Mexico

Irma Y Amaya-Larios  1 , Ruth Aralí Martínez-Vega  1 , Sandra V Mayer  1 , Marisol Galeana-Hernández  1 , Andreu Comas-García  1 , Karla J Sepúlveda-Salinas  1 , Jorge A Falcón-Lezama  1 , Nikos Vasilakis  1 , José Ramos-Castañeda  2
Affiliations

Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, Mexico

Irma Y Amaya-Larios et al. Am J Trop Med Hyg. 2014 Nov.

Abstract

Humoral immune response against dengue virus (DENV) is an important component in dengue-endemic transmission. We conducted a cross-sectional nested cohort study to determine the seroprevalence and frequency of neutralizing antibodies against DENV serotypes in two endemic localities in the state of Morelos, Mexico. The cohort participants (N = 1,196) were screened to determine previous exposure to DENV. Overall seroprevalence was 76.6% (95% confidence interval [95% CI] = 73.6-79.2), and prevalence of neutralizing antibodies in the 5- to 9-year-old group was 82.5% (95% CI = 67.2-92.7), 45% (95% CI = 29.3-61.5), and 65% (95% CI = 48.3-79.4) for DENV-1, DENV-2, and DENV-3, respectively. For participants older than 10 years, the observed seroprevalence was above 60% for each serotype, except DENV-4 in the 10- to 25-year-old group (42.9%); 81% of humoral responses were multitypic. The outcomes of our study contribute to understanding the immune component of dengue transmission and provide focal information for the evaluation of vaccine candidates under development.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Global seroprevalence of IgG against DENV by quinquennium in the localities of Axochiapan and Tepalcingo, Morelos, Mexico (2011). The graph shows the percentage of seroprevalence by quinquennium with 95% CI (error bars).
Figure 2.
Figure 2.
Seroprevalence per serotype against DENV per age group. Distribution of the seroprevalence by serotype per age group. The error bars are 95% CI. *Statistically significant differences.
Figure 3.
Figure 3.
Logarithm of neutralizing antibody titers against the four DENV serotypes (PRNT60). Mann–Whitney test. The error bars are 95% CI.
Figure 4.
Figure 4.
Logarithm of neutralizing antibody titers against the four DENV serotypes in recently infected and non-infected subjects (PRNT60). Mann–Whitney test. Comparison the logarithm of neutralizing antibody titers between recently infected and non-infected subjects. The error bars are 95% CI. *P = 0.0005 for DENV-1 infected (N = 38) versus DENV-1 (N = 99) not recently infected.
Figure 5.
Figure 5.
Neutralizing antibody titers per DENV serotype with respect to the type of response of the individuals. Mann–Whitney test. Comparison the logarithm of neutralizing antibody titers between homotypic and multitypic subjects. The error bars are 95% CI. *P < 0.0001 for homotypic response (N = 25) versus multitypic response (N = 111). **P < 0.005 for homotypic response for DENV-3 (N = 25) versus multitypic response for DENV-3 (N = 111).
See this image and copyright information in PMC

References

    1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. The global distribution and burden of dengue. Nature. 2013;496:504–507. - PMC - PubMed
    1. Sánchez-Burgos GG, López-Alvarado MA, Castañeda-Desales D, Ruiz-Gómez J, Ramos-Castañeda J. Prevalence of neutralizing antibodies to dengue virus serotypes in university students from Tabasco, Mexico. Salud Publica Mex. 2008;50:362–366. - PubMed
    1. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martínez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW. Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8((Suppl)):S7–S16. - PMC - PubMed
    1. Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21(st) century. Trop Med Health. 2011;39((Suppl)):3–11. - PMC - PubMed
    1. World Health Organization Dengue Guidelines, 2010. 2010. http://www.health.gov.bz/www/index.php/publications/environmental-health... Available at. Accessed July 7, 2011.

Publication types